Cassava Sciences GAAP EPS of -$0.22 beats by $0.02
at seekingalpha.com (Thu, 5-Nov 8:03 AM)
FLNA jumps after FDA lifts clinical hold, clearing a 40-patient Phase 2a path for simufilam in TSC-related epilepsy
Market Chameleon (Tue, 22-Sep 9:53 AM)
